肿瘤药学2019，Vol.9Issue(2)：256-260,266,6.DOI:10.3969/j.issn.2095-1264.2019.02.16
吉西他滨联合替吉奥或顺铂在治疗晚期胆囊癌中的疗效评估
Efficacy Evaluation on Gemcitabine Combined with S-1 or Cisplatin in the Treatment of Advanced Gallbladder Cancer
摘要
Abstract
Objective To investigate the effects of gemcitabine plus S-1 chemotherapy vs. gemcitabine plus cisplatin chemotherapy on advanced gallbladder cancer and its influence on serum tumor markers. Methods 78 patients with advanced gallbladder carcinoma in our hospital between January 2011 and February 2016 were selected as the research subjects. All patients were treated with palliative surgery. Then they were divided into treatment group (n=39) and control group (n=39) according to different treatment schemes. The treatment group was treated with gemcitabine plus S-1, while the control group was treated with gemcitabine plus cisplatin. The short-term effect, levels of serum tumor markers and serum growth factors, toxic reactions and survival status were compared between the two groups. Results The total remission rate and disease control rate did not have significant difference between the two groups (P>0.05). After treatment, the serum levels of β2-microglobulin (β2-MG), carbohydrate antigen 19-9 (CA19-9), carcinoembryonic antigen (CEA), and alpha fetoprotein (AFP) in the two groups were significantly lower than those before treatment (P<0.05). Moreover, after treatment, they were even lower in treatment group than in control group (P<0.05). As for the serum levels of vascular endothelial growth factor (VEGF), matrix metalloproteinase-1 (MMP-1), and basic fibroblast growth factor (FGF), they were found after treatment significantly lower than before treatment (P<0.05), and were sig- nificantly lower in treatment group than in control group after treatment (P<0.05). In addition, the incidence rate of grade Ⅲ-Ⅳ toxic reac-tions in neutrophils, nausea and vomiting in the treatment group was lower than in the control group (P<0.05). The median progression free time and median overall survival time were longer and survival rate were higher in the treatment group than in the control group (P<0.05). Conclusion The short-term efficacy of gemcitabine plus S-1 is similar to that of gemcitabine plus cisplatin in the treatment of advanced gallbladder cancer. But gemcitabine plus S-1 chemotherapy could significantly improve the levels of serum tumor markers and serum growth factors, reduce the toxicity and prolong the survival time to a certain extent.关键词
姑息性手术/吉西他滨/替吉奥/胆囊癌/血清肿瘤标志物Key words
Palliative surgery/Gemcitabine/S-1/Carcinoma of gallbladder/Serum tumor markers分类
医药卫生引用本文复制引用
WANG Zhiping,LIU Xia,LUO Juan..吉西他滨联合替吉奥或顺铂在治疗晚期胆囊癌中的疗效评估[J].肿瘤药学,2019,9(2):256-260,266,6.基金项目
四川省卫生厅科研基金项目(150178). （150178）
